Skip to Content

Advanced Proteome Therapeutics Corp APTCF

Morningstar Rating
$0.00 −0.04 (99.46%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

APTCF is trading at a 73% premium.
Price
$0.00
Fair Value
$8.84
Uncertainty
Extreme
1-Star Price
$7.20
5-Star Price
$2.39
Economic Moat
Llmmxx
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APTCF is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.04
Day Range
$0.000.00
52-Week Range
$0.000.00
Bid/Ask
$0.01 / $0.20
Market Cap
$8,225.42
Volume/Avg
14,490 / 14,490

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Advanced Proteome Therapeutics Corp is a biotechnology company. It develops and commercializes a platform to use protein modification technologies to create proprietary human protein pharmaceuticals with therapeutic properties. The company develops anti-cancer drugs for cancerous tumors that will destroy a cancer patient's tumor cells selectively, sparing healthy cells. All the operations of the organization are principally carried out in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
5

Valuation

Metric
APTCF
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
APTCF

Financial Strength

Metric
APTCF
Quick Ratio
0.73
Current Ratio
0.73
Interest Coverage
−60.57
Quick Ratio
APTCF

Profitability

Metric
APTCF
Return on Assets (Normalized)
−230.48%
Return on Equity (Normalized)
−194.29%
Return on Invested Capital (Normalized)
Return on Assets
APTCF
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
MmlhyxtgbBpccm$631.1 Bil
Vertex Pharmaceuticals Inc
VRTX
ZjyskhwvMfcszd$120.6 Bil
Regeneron Pharmaceuticals Inc
REGN
ThnsdtkVglqm$114.5 Bil
Moderna Inc
MRNA
PrpkflzsSvy$51.1 Bil
argenx SE ADR
ARGX
CsbxbwsJzrnl$22.6 Bil
BioNTech SE ADR
BNTX
HtypcpbnZkcd$20.8 Bil
Alnylam Pharmaceuticals Inc
ALNY
NxryznmQvbpxx$19.5 Bil
Biomarin Pharmaceutical Inc
BMRN
MtrskzzhXgfkhl$16.0 Bil
United Therapeutics Corp
UTHR
HqnjnzfBll$13.6 Bil
Incyte Corp
INCY
TtlsfvqKvkmf$12.1 Bil

Sponsor Center